*Disseminated on Behalf of Alzamend Neuro, Inc. Please see disclosures below. |
| Phase II Trial Is Underway For Alzamend |
| | | | | Folks, Alzamend Neuro, Inc. (ALZN) is a clinical-stage biopharmaceutical company developing novel treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The company recently announced the initiation of its Phase II clinical trial evaluating AL001 in patients diagnosed with bipolar disorder type I.
The trial is being conducted at Massachusetts General Hospital and marks a key step in advancing AL001 as a potentially safer and more effective lithium-based therapy. This Phase II study builds on Alzamend's prior "Lithium in Brain" clinical trial in healthy subjects, for which the clinical portion was completed in November 2025.
Topline data from that earlier study are expected by the end of March 2026. The company also plans to initiate additional trials in major depressive disorder, Alzheimer's disease, and PTSD in the near future.
Anyways...
That's all for now!
Until Next Time, -ZT Team | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Disseminated on Behalf of Alzamend Neuro, Inc. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| This email was sent to reunisoft.cryptonews@blogger.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via YouTube, email, and SMS on behalf of Alzamend Neuro, Inc. (ALZN) from March 25, 2026 to March 26, 2026. ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for Alzamend Neuro, Inc. (ALZN). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Alzamend Neuro, Inc. (ALZN). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Alzamend Neuro, Inc. (ALZN), increased trading volume, and possibly an increased share price of Alzamend Neuro, Inc. (ALZN), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service. See Our Advertisement Disclaimer. |
| | |
|
|
|---|
|
|
|
No comments:
Post a Comment